Advertisement

James P. Allison, PhD


Advertisement
Get Permission

James P. Allison, PhD

James P. Allison, PhD

James P. Allison, PhD, is Chair of Immunology and Executive Director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center in Houston. In 2018, Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine, with Tasuku Honjo, MD, PhD, for launching an effective new way to attack cancer by treating the immune system rather than the tumor.

Dr. Allison’s work led to the development of the first immune checkpoint inhibitor—ipilimumab, which was approved by the U.S. Food and Drug Administration in 2011 for treatment of late-stage melanoma. 


Related Articles

Cancer Researcher Continues to Push the Envelope in Immunotherapy to Help Patients Live Longer

Padmanee Sharma, MD, PhD

Padmanee Sharma, MD, PhD

Nationally regarded cancer immunologist Padmanee Sharma, MD, PhD, was born and reared in Georgetown, Guyana, on South America’s North Atlantic coast, noted for being the only South American country in which English is the official language. Her parents were...

Advertisement

Advertisement



;
Advertisement